Introduction
Retroperitoneal fibrosis (RPF) was first described by Albarran [1] 112 years ago, but there are still no published guidelines on how to manage this disease [2] . Ureteric obstruction is one of the most serious sequelae of RPF, and whilst the placement of ureteric stents is accepted as the best initial management, the optimum long-term management of ureteric obstruction is still debated [2] [3] [4] [5] . In essence, the role of ureterolysis is undecided: is ureterolysis an operation that should only be considered for refractory obstruction and/or problematic stent symptoms, or should it be offered as a definitive treatment for ureteric obstruction caused by RPF?
Ureterolysis was first reported for the treatment of ureteric obstruction in RPF in 1934 [6] . The morbidity and poor outcomes of ureterolysis [7] , coupled with the advent of endourology, led to the adoption of a more conservative management strategy. There are several reports of successful management of ureteric obstruction with stents and steroids [5, 8, 9] , even though the optimum regimen is yet to be defined. Whilst the relatively low initial morbidity of this strategy is appealing, the cumulative morbidity over time may be more problematic [10, 11] . In 2017 the best long-term strategy is still unclear.
In addressing this issue there are a number of important considerations, including stent-free rates and the impact on renal function of different management strategies, the morbidity of long-term stenting and prolonged courses of steroids, the morbidity of major surgery, and the incidence of recurrent obstruction from relapsing RPF. The picture is further complicated by the number of different pathological processes that may lead to RPF and the realization that each of these diseases may require different approaches to treatment [4, [12] [13] [14] . Furthermore, it may be that outcomes for patients with severe residual obstruction, despite stenting, e.g. patients with nephrostomy-dependent drainage, might be very different from those in patients with severe stent symptoms but no residual obstruction.
One of the reasons that the role of ureterolysis remains unclear is that RPF is a rare disease and single urological surgical units have not been able to accrue sufficient numbers of cases to be more sure of its effectiveness. The urological literature contains relatively few reports of ureterolysis series [15] [16] [17] [18] [19] , and the largest multi-institutional survey contained only 73 cases in total from 17 centres [20] . Management in low-volume units may also lead to a perception of the operation being particularly technically challenging or associated with a very high risk of complications. This perception may lead to persistence with conservative management, despite evidence of ongoing ureteric obstruction and/or highly problematic side effects from steroids and/or stents. The establishment of specialist treatment centres for RPF may potentially alter that perception.
In 2012 we established a multidisciplinary service for RPF at Guys Hospital in London. The team has comprised urologists, a nephrologist, a rheumatologist, a pathologist, radiologists, pain specialists and a nurse. Since 2012, 176 patients have been seen. The aims have been to accelerate progress in our understanding of the disease and, in particular, to define the principal goals of investigation and treatment, to formulate a classification, to describe a coherent plan of initial investigation, and to understand the best long-term management of ureteric obstruction. Progress has been made in optimizing initial management and has identified CTpositron-emission tomography (PET) as a useful tool in judging both the need for biopsy and whether the patient is likely to respond to steroids [21] . In the present study, we examine the outcomes of ureterolysis and, in so doing, attempt to clarify the role of ureterolysis in the modern management of ureteric obstruction caused by RPF.
Methods
We conducted a prospective study of all patients undergoing open ureterolysis between January 2012 and January 2016, who had completed a minimum of 1 year follow-up. Patients were recruited from a multidisciplinary RPF clinic at Guy's Hospital in London. All operations were performed by a single surgical team.
Indications for surgery were: nephrostomy-dependent drainage; stent failure, as evidenced by persistent hydronephrosis; severe stent symptoms; and patient choice (pre-emptive). In the period of the study 11 patients had ureteric obstruction amenable to ureterolysis but five refused surgery, preferring endourological approaches, and six were considered unfit for major surgery because of multiple comorbidities. Formal quantification of stent symptoms was not undertaken.
Outcome measures were: the stent-free rate; change in renal function post-ureterolysis (change in GFR as a percentage of baseline GFR); operating variables (operating time including additional procedures, blood loss, complications, length of hospital stay); and need for further intervention. Complications were classified using the Clavien system.
Our approach has been to stent ureters in the weeks prior to the procedure and to perform retrograde ureterograms to define the anatomical location of maximum obstruction. Steroids were tailored down to a maximum of 5 mg once daily prior to surgery. All the operations were performed through a midline incision under general anaesthesia. The colon was reflected medially to reveal the RPF plaque. The stented ureter was identified just below the PUJ. It was then mobilized distally to the point of apparent maximum obstruction, usually over the common iliac artery. The ureter was then identified in the true pelvis and mobilized proximally to the point of maximum obstruction (Fig. 1 ). This final dissection of the most involved section of the ureter carries the highest risk of ureteric injury. The ureter was mobilized from the fibrosis using a combination of sharp and blunt dissection. The ideal plane between the ureteric wall and the RPF plaque is relatively avascular. In the majority of cases the ureter was mobilized from just below the PUJ to the level of the mid-true pelvis. After ureterolysis an omental graft was fashioned and placed between the ureter and RPF (Fig. 2A) . The omentum was then tubularized around the ureter (Fig. 2B) . If omentum was not available then peri-renal or peri-colonic fat was interposed between ureter and fibrosis. The stents were removed under local anaesthesia 3-6 weeks after the procedure. Renal function was checked preoperatively, on discharge from hospital, and at 3 and 12 months post-ureterolysis. Renograms and CT were not routinely performed as part of follow-up. Imaging with CT, PET and/or renography was used if there was any decline in GFR or change in symptoms.
Continuous variables are described as median and interquartile range (IQR), while categorical variables are described as frequency and percentage. Renal function before and after ureterolysis was analysed using Wilcoxon matchedpair analysis (GraphPad). P values <0.05 were taken to indicate statistical significance.
Results
A total of 50 patients underwent ureterolysis. Of these, 31 were men and 19 women. The median (range) age was 58 (40-77) years. The median (range) time stented prior to ureterolysis was 38 months (4 months to 10 years). Indications for surgery were 5/50 (10%) nephrostomydependent; 20/50 (40%) stent failure; 22/50 (44%) stent symptoms; and 3/50 (6%) pre-emptive/patient choice.
Patients' preoperative chronic kidney disease (CKD) status was: stage 1, n = 3; stage 2, n = 19; stage 3a, n = 14; stage 3b, n = 10; stage 4, n = 4; and stage 5, n = 0. The median followup was 21 (12-48) months.
The operating and additional intra-operative characteristics are outlined in Table 1 . Notably, 22% of patients underwent additional intra-operative procedures ( Table 1 ). The surgical complications are shown in Table 2 ; 12% of patients had a Clavien III or IV complication.
A total of 48/50 (96%) patients were stent-free at 3 months post-ureterolysis and 47/50 (94%) were stent-free at 12 months. The renal function outcomes at 3 and 12 months postoperatively are shown in Table 3 , stratified by indication. There was significant improvement in GFR overall (median improvement +6%; P < 0.05; 95% CI 0.6-7.6) and in the group of patients in whom the indication was stent failure (median improvement +25%; P < 0.001; 95% CI 4.3-5.8). 
Discussion
The surgical literature on ureterolysis dates from 1934 and there are more than 30 series/case reports; all are retrospective, most include very low numbers and tend to include operations accumulated over a very long period of time. There have been no prospective series of the outcomes of open ureterolysis published. The present prospective series has been accumulated over a relatively short time period, is contemporary, and is that of a high-volume team, and so may provide a benchmark for the management of ureteric obstruction caused by RPF.
The most striking aspect of the present study is the number of patients rendered stent-free by ureterolysis: 96% were stent-free 3 months after the procedure. All but one of those patients remain stent-free after the first year. This is particularly surprising given that half of patients had refractory RPF; that is, had failed endourological management, either because they were nephrostomydependent or obstructed despite stents. Furthermore all five patients who were nephrostomy-dependent remain nephrostomy-and stent-free after ureterolysis. It appears that in all patients, even those with refractory obstruction from RPF, ureterolysis provides an excellent chance of being stentfree in the short to medium term. Ureteric stents can be highly symptomatic and frequent stent changes disruptive and expensive; therefore freedom from stents seems a desirable goal even in those patients who are adequately drained with stents [2] .
Overall, it appears that patients experience improvement in their renal function after ureterolysis, with a quarter of patients having an increase in GFR of >20% post-ureterolysis (Table 3 ). Significant gains in GFR were seen in the 'stent failure' group (Table 3) . Gains in this group were greater than those seen in those undergoing ureterolysis principally for stent symptoms or pre-emptively. Unsurprisingly, GFR did not increase in patients who were nephrostomydependent pre-ureterolysis, but no patient who was nephrostomy-dependent had a significant decrease in GFR.
Severe CKD (stage >3) should not exclude patients from ureterolysis. In fact, 96% of patients with CKD stage >3 had stable or improved renal function after ureterolysis.
There were three significant failures of treatment intent: firstly, a patient with post-radiation RPF and CKD stage 4 who had stent-dependent RPF sustained an intra-operative ureteric injury, never became stent-free and is now dialysisdependent; secondly, a patient with pan-ureteric obstruction within 3 months of ureterolysis required nephrectomy for non-function at 6 months; and thirdly, a patient was referred for redo-exploration to our unit after an attempt at RPF biopsy, complicated by bleeding and thrombosis. The ureterolysis was completed successfully but the patient had to be re-stented at 1 year because of re-obstruction and CKD stage 5.
The present study shows that the morbidity of modern open ureterolysis is significant but manageable. In this series there Table 2 Complications (N = 13).
Complication n (%) Type
Clavien I 1 (2) Superficial wound breakdown Clavien II 6 (12) Ileus (3) Pneumonia (2) UTI (1) Clavien III 4 (8) Laparotomy for small bowel obstruction (n = 1) Urine leak requiring nephrostomy (n = 1) Left femoral artery embolus at 3 weeks (n = 1) Acute incisional hernia (n = 1) Clavien IV 2 (4) Pulmonary embolus Urosepsis requiring ITU <0.05 +6 (À4 to +22) (95% CI 0.6 to 7.6)
<0.05
Nephrostomy-dependent (N = 5) 45 (18-68) +0 (À16 to +20) (95% CI À6.5 to 7.6) were no vascular or bowel injuries. There were three ureteric injuries, which in two cases were successfully primarily repaired but repair was unsuccessful in one patient with radiotherapy-induced RPF (see above). The mean operating time was 3 h and mean length of hospital stay was just over 1 week. Nevertheless, the surgery can be very challenging and additional procedures were required in 20% of patients. Serious complications (Clavien grades III or IV) were seen in six patients (12%). An omental wrap was fashioned in all but two cases. The importance of the wrap is not known, in particular, whether it simply acts a barrier to further encroachment by fibrosis or whether it acts to nourish and re-vascularize the lysed ureter. The segmental vascular supply of 10-20 cm of ureter is compromised by ureterolysis and it is perhaps surprising that ureteric strictures or pan-ureteric ischaemic fibrosis are not seen more commonly.
The ureterolysis operations in this series were performed via an open approach for three reasons: firstly, the expertise of the lead RPF surgeon is in open surgery; secondly, the patients were mainly tertiary referrals with complicated RPF, many with IgG4-related disease, requiring long-length ureterolysis; and thirdly, our concern since establishment of the service in 2012 has been to deliver ureterolysis consistently and safely and, in so doing, establish a modern benchmark for outcomes. It was our view that little could or would be learned from an inconsistent approach where open and minimal access approaches were mixed ad hoc. Case reports of laparoscopic and robot-assisted ureterolysis date from 1992 [22] , but almost all series are retrospective and many include <10 cases [17, 19, [22] [23] [24] [25] . Notable series from Michigan and New York compare laparoscopic and open outcomes, but the controls were historical with all the attendant risks of selection bias [16, 18] . Having established a benchmark, we are now attempting to deliver the outcomes of open ureterolysis with potentially less morbidity by using robot-assisted laparoscopic approaches in our centre, which has expertise in robotics. Accordingly, since January 2016, our default position has been to offer robot-assisted ureterolysis and the early results are encouraging (Fernando et al. abstract on prospective outcomes of robot-assisted ureterolysis, to be presented at European Association of Urology, 2017). Clearly whether the outcomes of robotassisted ureterolysis compare favourably with open surgery will be of interest.
In the present series the median (range) time during which patients were stented, from diagnosis to referral to our unit for ureterolysis, was 38 months (2 months to 10 years), highlighting the often protracted nature of decision-making in this disease. The majority of these patients appear to be being considered for ureterolysis as a treatment of last resort, having failed endourological management. The excellent stent-free rates and functional outcomes of ureterolysis beg the question as to whether it should continue to be reserved as a treatment of last resort or should be considered earlier in the treatment pathway of patients presenting with ureteric obstruction. Our current policy is to offer ureterolysis to patients who are not stent-free within 6 months of initiating medical treatment. In this regard, PET scanning may be useful in directing treatment decisions; if the RPF is non-avid or weakly avid then patients are unlikely to respond to steroids and ureterolysis could be offered as a primary treatment [21] . What would also be valuable in this regard would be a clear consensus from patients as to what they would consider successful management in RPF. The development of a patient-reported outcome measure is a research priority.
There are a number of limitations to this study. It is difficult to know how applicable the results of treating patients with refractory RPF in a tertiary referral practice are to all patients presenting with ureteric obstruction from RPF. A national prospective study of all patients presenting with ureteric obstruction is a research priority. In addition, complex surgical techniques were used and it may not be feasible for all centres to offer ureterolysis or to deliver successful outcomes. Lastly, only medium-term follow-up is currently available and prospective collation of longer-term outcomes is ongoing.
In conclusion, the present study suggests that, for patients with ureteric obstruction from RPF, contemporary ureterolysis performed by a high-volume specialist team can successfully render patients stent-or nephrostomy-free with optimum renal function. The results suggest that ureterolysis should be considered in all patients who present with ureteric obstruction from RPF that does not respond quickly to medical treatment. A priority now is to reproduce these results with minimal access approaches to reduce the morbidity of the procedure whilst maintaining its effectiveness.
